Registro:

Referencias:

• Chang, G.W.M., Kam, P.C.A., The physiological and pharmacological roles of cytochrome P450 isoenzymes (1999) Anaesthesia, 54, pp. 42-50
• Ingelman-Sundberg, M., The human genome project and novel aspects of cytochrome P450 research (2005) Toxicol. Appl. Pharmacol., 207, pp. 552-556
• Burroughs, V.J., Maxey, R.W., Levy, R.A., Racial and ethnic differences in response to medicines: Toward individualized pharmaceutical treatment (2002) J. Natl. Med. Assoc., 94, pp. 1-26
• Ingelman-Sundberg, M., Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity (2005) Pharmacogenomics J., 5, pp. 6-13
• Scordo, M.A., Caputi, A.P., D'Arrigo, C., Fava, G., Spina, E., Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population (2004) Pharmacol. Res., 50, pp. 195-200
• Ingelman-Sundberg, M., Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future (2004) Trends Pharmacol. Sci., 25, pp. 193-200
• Saxena, R., Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with poor metabolizer phenotype (1994) Hum. Mol. Gen., 3, pp. 923-926
• Sachse, C., Brockmoller, J., Bauer, S., Roots, I., Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences (1997) Am. J. Hum. Genet., 60, pp. 284-295
• Van Der Weide, J., Steijns, L., Cytochrome P450 enzyme system: Genetic polymorphisms and impact on clinical pharmacology (1999) Ann. Clin. Biochem., 36, pp. 722-729
• Batlle, A.M.D.C., Porfirinas y porfirias: Aspectos clínicos, bioquímicos y biología molecular. Serie: Actualizaciones Médico- Bioquímicas (1997) Acta Bioquím. Latinoamer., (SUPPL. 3), pp. 3-63
• Nordmann, Y., Puy, H., Deybach, J.C., The porphyrias (1999) J. Hepatol., 30, pp. 12-16
• Thadani, H., Deacon, A., Peters, T., Diagnosis and management of porphyria (2000) Br. Med. J., 320, pp. 1647-1651
• Meyer, U.A., Schuurmans, M.M., Lindberg, R.L., A review of the pathogenesis of the neurological manifestations of the acute porphyrias (1998) Semin. Liver Dis., 18, pp. 43-52
• Méndez, M., Rossetti, M.V., Batlle, A.M.D.C., Parera, V.E., The role of inherited and acquired factors in the development of porphyria cutanea tarda in the Argentinean population (2005) J. Am. Acad. Dermatol., 52, pp. 417-424
• Daly, A.K., Steen, V.M., Fairbrother, K.S., Idle, J.R., CYP2D6 Multiallelism (1996) Methods in Enzymology: Cytochrome P450, 272, pp. 199-211. , Waterman MR, Johnson EF (eds.) Academic Press, chapter 22
• Lennard, M.S., Genetic polymorphism of sparteine/debrisoquine oxidation: A reappraisal (1990) Pharmacol. Toxicol., 67, pp. 273-283
• Bertilsson, L., Dahl, M.L., Dalen, P., Al-Shurbaji, A., Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs (2002) Br. J. Clin. Pharmacol., 53, pp. 111-122
• Marez, D., Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution (1997) Pharmacogenetics, 7, pp. 193-202
• Bradford, L.D., CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants (2002) Pharmacogenomics, 3, pp. 229-243
• Meyer, U.A., Zanger, U.M., Molecular mechanisms of genetic polymorphisms of drug metabolism (1997) Annu. Rev. Pharmacol. Toxicol., 37, pp. 269-296
• Cascorbi, I., Pharmacogenetics of cytochrome P4502D6: Genetic background and clinical implication (2003) Eur. J. Clin. Invest., 33, pp. 17-22
• Caporaso, N., Landi, M.T., Vineis, P., Relevance of metabolic polymorphisms to human carcinogenesis: Evaluation of epidemiologic evidence (1991) Pharmacogenetics, 1, pp. 4-19
• Agündez, J.A., Debrisoquin oxidation genotype and susceptibility to lung cancer (1994) Clin. Pharmacol. Ther., 55, pp. 10-14
• Anwar, W.A., Abdel-Rahman, S.Z., El-Zein, R.A., Mostafa, H.M., Au, W.W., Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients (1996) Carcinogenesis, 17, pp. 1923-1929
• Agündez, J.A., Ledesma, M.C., Benitez, J.M., Ladero, J.M., Rodriguez-Lescure, A., Diaz-Rubio, E., Diaz-Rubio, M., CYP2D6 genes and risk of liver cancer (1995) Lancet, 345, pp. 830-831
• Wolf, C.R., Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility (1992) Carcinogenesis, 13, pp. 1035-1038
• Anthony, L.B., Thomas, J.B., Hande, K.R., Cytochrome P-450IID6 phenotyping in cancer patients: Debrisoquine and dextromethorphan as probes (1995) Cancer Chemother. Pharmacol., 36, pp. 125-128
• Topic, E., Stefanovic, M., Ivanisevic, A.M., Petrinovic, R., Curcic, I., The cytochrome P450 2D6 (CYP2D6) gene polymorphism among breast and head and neck cancer patients (2000) Clin. Chim. Acta, 296, pp. 101-109
• Gardlo, K., Selimovic, D., Bolsen, K., Ruzicka, T., Abel, J., Fritsch, C., Cytochrome P4501A1 polymorphisms in a Caucasian population with porphyria (2003) Exp. Dermatol., 12, pp. 843-848
• Christiansen, L., Bygum, A., Jensen, A., Thomsen, K., Brandrup, F., Horder, M., Petersen, N.E., Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda (2000) Hum. Genet., 107, pp. 612-614
• Spear, B., Heath-Chiozzi, M., Huff, J., Clinical application of pharmacogenetics (2001) Trend Mol. Med., 7, pp. 201-204

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------